During the discussion, Alan Venook, MD, of Helen Diller Comprehensive Cancer Center, University of California, San Francisco, raised the concern that nab-paclitaxel appears to be the platform of choice for clinical trials going forward. “I’m not sure if this is based on market or merit,” he commented.
“I’m concerned that we’ll do studies with gemcitabine and nab-paclitaxel as the platform and combine these two drugs with other drugs with no scientific basis. It’s much harder to get FOLFIRINOX studies supported,” Dr. Venook said. “Science should guide which drugs are used to combine with nab-paclitaxel.” ■
Disclosure: Dr. Venook reported no potential conflicts of interst.
The choice between FOLFIRINOX (fluorouracil [5-FU], leucovorin, irinotecan, oxaliplatin) vs the combination of gemcitabine and nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) for first-line treatment of metastatic pancreatic cancer is not much of a contest, judging by a discussion of...